CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −21,926 | $62.03 | $1.4M | 120,963 |
| 2026-09-15 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −13,874 | $62.63 | $869K | 107,089 |
| 2026-09-15 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −1,400 | $63.69 | $89K | 105,689 |
| 2026-09-15 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −300 | $65.31 | $20K | 105,389 |
| 2026-09-15 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −37,500 | 0 | ||
| 2026-09-10 | Meckler Jeffrey A Director | Option exercise 10b5-1 | +10,000 | $17.44 | $174K | 101,500 |
| 2026-09-10 | Meckler Jeffrey A Director | Option exercise 10b5-1 | +10,000 | $26.52 | $265K | 111,500 |
| 2026-09-10 | Meckler Jeffrey A Director | Sale 10b5-1 | −1,700 | $65.39 | $111K | 109,800 |
| 2026-09-10 | Meckler Jeffrey A Director | Sale 10b5-1 | −1,200 | $66.15 | $79K | 108,600 |
| 2026-09-10 | Meckler Jeffrey A Director | Sale 10b5-1 | −14,000 | $67.46 | $944K | 94,600 |
| 2026-09-10 | Meckler Jeffrey A Director | Sale 10b5-1 | −3,100 | $68.09 | $211K | 91,500 |
| 2026-09-10 | Meckler Jeffrey A Director | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2026-09-10 | Meckler Jeffrey A Director | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2026-09-02 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −642 | $66.37 | $43K | 118,016 |
| 2026-08-18 | LYONS GARY A Director | Option exercise 10b5-1 | +5,000 | $17.44 | $87K | 66,500 |
| 2026-08-18 | LYONS GARY A Director | Sale 10b5-1 | −4,100 | $63.27 | $259K | 62,400 |
| 2026-08-18 | LYONS GARY A Director | Sale 10b5-1 | −900 | $63.86 | $57K | 61,500 |
| 2026-08-18 | LYONS GARY A Director | Option exercise · Stock option (right to buy) 10b5-1 | −5,000 | 0 | ||
| 2026-08-17 | LYONS GARY A Director | Option exercise 10b5-1 | +5,000 | $17.44 | $87K | 66,500 |
| 2026-08-17 | LYONS GARY A Director | Sale 10b5-1 | −1,900 | $62.53 | $119K | 64,600 |
Page 5 of 41 · 802 trades